Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced updates for three of its next-generation adeno-associated virus (AAV)-based therapy programs: ADVM-043, targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE